GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » MediPharm Labs Corp (TSX:LABS) » Definitions » LT-Debt-to-Total-Asset

MediPharm Labs (TSX:LABS) LT-Debt-to-Total-Asset : 0.00 (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is MediPharm Labs LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. MediPharm Labs's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.00.

MediPharm Labs's long-term debt to total assets ratio stayed the same from Sep. 2023 (0.00) to Sep. 2024 (0.00).


MediPharm Labs LT-Debt-to-Total-Asset Historical Data

The historical data trend for MediPharm Labs's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MediPharm Labs LT-Debt-to-Total-Asset Chart

MediPharm Labs Annual Data
Trend Sep17 Sep18 Dec19 Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.05 0.09 - - -

MediPharm Labs Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

MediPharm Labs LT-Debt-to-Total-Asset Calculation

MediPharm Labs's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=0.069/63.937
=0.00

MediPharm Labs's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )/Total Assets (Q: Sep. 2024 )
=0.035/55.844
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MediPharm Labs  (TSX:LABS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


MediPharm Labs LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of MediPharm Labs's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


MediPharm Labs Business Description

Traded in Other Exchanges
Address
151 John Street, Barrie, ON, CAN, L4N 2L1
MediPharm Labs Corp is a pharmaceutical company specializing in precision-based cannabinoids. The Company operates in one reportable segment, the production and sales of cannabis flower, extracts, and derivative products. Through its wholesale and white-label platforms, MediPharm Labs formulates, develops, processes, packages, and distributes cannabis extracts and cannabinoid-based products to domestic and international markets. Geographically the company has a presence in Canada, Australia, Germany, and other countries and the majority of revenue derives from Canada.
Executives
Keith Strachan Director
Gregory Edison Hunter Senior Officer
David Pidduck Director, Senior Officer
Bryan Howcroft Director, Senior Officer
Patrick Mccutcheon Director
Warren Everitt Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Etf Managers Trust 10% Security Holder
Christopher David Taves Director
Sybil Taylor Senior Officer
Braden Fenske Senior Officer
David John Mayers Senior Officer

MediPharm Labs Headlines